The aim of this review is to describe the sub-population of CCS at greatest risk for development of GHD and to highlight the most recent literature on the safety profile of GH therapy with respect to tumor recurrence and secondary malignancies in childhood cancer survivors. Here, GH1 is linked to neoplasm.